Celularity Inc (CELU) stock

CELUNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Oct 20, 2026Score 7/30

$0.68−0.07 (-8.81%)

Close on Nov 12, 2026Market cap $22.22MP/E –Yield –

Celularity operating margin

Operating margin is operating income as a percentage of revenue.

Celularity's operating margin for the twelve months ending Jun 30, 2026 was -264.3%. For fiscal 2025 it was -230.9%, against -70.7% the year before. The highest annual figure on record is -70.7% in fiscal 2024.

Annual operating margin

Period	Period end	Value	Change (pts)
FY2025	Dec 31, 2025	-230.9%	−160.2
FY2024	Dec 31, 2024	-70.7%	+773.7
FY2023	Dec 31, 2023	-844.4%	−702.0
FY2022	Dec 31, 2022	-142.4%	+368.8
FY2021	Dec 31, 2021	-511.2%	+552.9
FY2020	Dec 31, 2020	-1064.0%	–

Quarterly operating margin

Change is against the same quarter a year earlier.

Period	Period end	Value	Change (pts)
Q2 FY2026	Jun 30, 2026	-78.0%	+198.6
Q1 FY2026	Mar 31, 2026	-263.5%	−171.7
Q4 FY2025	Dec 31, 2025	-537.5%	−486.3
Q3 FY2025	Sep 30, 2025	-244.1%	−120.1
Q2 FY2025	Jun 30, 2025	-276.6%	−192.6
Q1 FY2025	Mar 31, 2025	-91.8%	−41.5
Q4 FY2024	Dec 31, 2024	-51.2%	−161.1
Q3 FY2024	Sep 30, 2024	-124.0%	+2497.7
Q2 FY2024	Jun 30, 2024	-84.0%	+1361.7
Q1 FY2024	Mar 31, 2024	-50.2%	+1572.9
Q4 FY2023	Dec 31, 2023	109.9%	−313.5
Q3 FY2023	Sep 30, 2023	-2621.7%	−2485.1
Q2 FY2023	Jun 30, 2023	-1445.7%	−1556.3
Q1 FY2023	Mar 31, 2023	-1623.1%	−922.0
Q4 FY2022	Dec 31, 2022	423.5%	+731.4
Q3 FY2022	Sep 30, 2022	-136.5%	−239.1
Q2 FY2022	Jun 30, 2022	110.6%	+2006.4
Q1 FY2022	Mar 31, 2022	-701.2%	+967.8
Q4 FY2021	Dec 31, 2021	-307.9%	−648.8
Q3 FY2021	Sep 30, 2021	102.6%	+245.8
Q2 FY2021	Jun 30, 2021	-1895.9%	–
Q1 FY2021	Mar 31, 2021	-1669.0%	–
Q4 FY2020	Dec 31, 2020	340.9%	–
Q3 FY2020	Sep 30, 2020	-143.2%	–